NASDAQ:CRDF Cardiff Oncology Q1 2025 Earnings Report $4.07 -0.09 (-2.16%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.06 -0.02 (-0.37%) As of 07/11/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Cardiff Oncology EPS ResultsActual EPS-$0.20Consensus EPS -$0.19Beat/MissMissed by -$0.01One Year Ago EPSN/ACardiff Oncology Revenue ResultsActual Revenue$0.11 millionExpected Revenue$0.09 millionBeat/MissBeat by +$21.00 thousandYoY Revenue GrowthN/ACardiff Oncology Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time4:00PM ETUpcoming EarningsCardiff Oncology's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cardiff Oncology Earnings HeadlinesCardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.70 Consensus PT from Analysts4 hours ago | americanbankingnews.comLadenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy RecommendationJuly 9, 2025 | msn.comHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning. | Timothy Sykes (Ad)While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the mostJuly 3, 2025 | finance.yahoo.comCRDF - Cardiff Oncology Inc Ownership - MorningstarJuly 2, 2025 | morningstar.comMCardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low OpportunityJune 27, 2025 | seekingalpha.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF) is a clinical-stage biotechnology company focused on developing personalized combination therapies for the treatment of cancer. By leveraging its proprietary OncoSignature platform, the company integrates genomic, transcriptomic and proteomic data to predict synergistic interactions between immuno-oncology agents and targeted drugs. Cardiff Oncology’s approach aims to move beyond single-agent therapies by identifying optimal regimens that address the complexity and heterogeneity of tumor biology. The company’s pipeline includes multiple combination therapy candidates in clinical trials for various solid tumors and hematological malignancies. Its lead programs explore the use of checkpoint inhibitors in tandem with small-molecule inhibitors and monoclonal antibodies, with early data demonstrating potential benefits in tumor response rates. Cardiff Oncology also collaborates with academic medical centers and contract research organizations to accelerate the design and execution of its clinical studies. Founded in 2012 and headquartered in San Diego, California, Cardiff Oncology has expanded its research and development operations across the United States. Since inception, the company has built a multidisciplinary team of scientists, clinicians and data analysts dedicated to precision oncology. In recent years, Cardiff Oncology has entered strategic partnerships to enhance its translational research capabilities, drawing on expertise in bioinformatics and molecular diagnostics. Cardiff Oncology is led by an executive team with extensive experience in oncology drug development, regulatory affairs and commercial strategy. The company’s leadership includes veterans from major pharmaceutical and biotechnology firms, underscoring its commitment to advancing innovative cancer therapies. With a focus on personalized medicine and data-driven insights, Cardiff Oncology seeks to deliver new combination treatments that improve outcomes for patients with difficult-to-treat cancers.Written by Jeffrey Neal JohnsonView Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
